No Detail Found!

Comparison of Safety and Efficacy of Intravitreal Ziv- Aflibercept Vs Bevacizumab for the Treatment of Macular Edema

Author(s)
Hussain Ahmad Khaqan Ameer-ud-Din Medical College PGMI, Lahore General Hospital, Lahore, Pakistan
Usman Imtiaz Ameer-ud-Din Medical College PGMI, Lahore General Hospital, Lahore, Pakistan
Hasnain Muhammad Buksh Ameer-ud-Din Medical College PGMI, Lahore General Hospital, Lahore, Pakistan
Hafiz Ateeq-ur-Rehman Ameer-ud-Din Medical College PGMI, Lahore General Hospital, Lahore, Pakistan
Raheela Naz Ameer-ud-Din Medical College PGMI, Lahore General Hospital, Lahore, Pakistan
Abstract
Purpose: To study the safety and efficacy of intravitreal Ziv-Aflibercept vs. Bevacizumab for the management of edema caused by different retinal pathologies. Study Design: Comparative interventional study. Material and Methods: All patients with resistant, center involving macular edema due to diabetes, retinal vein occlusion and age related macular degeneration were recruited in this study. Complete baseline ocular examination was performed at presentation. All the patients were randomly grouped into two i.e. IVZ (intravitreal Ziv-Aflibercept) and IVB (intravitreal bevacizumab). Each eye underwent intravitreal injection of 0.05 ml of fresh filtered ziv-aflibercept (1.25 mg) or 0.05 ml of fresh filtered Bevacizumab. Outcome was measured in terms of variation in central macular thickness (CMT) and also best corrected visual acuity (BCVA) at 3 months. Results: Total of 156 eyes of 136 patients completed whole duration of study and were included in the results. The mean baseline CMT was 510 µm (± 94 µm) in the IVB group and 493µm (±102 µm) in the IVZ group (P = 0.94). The mean baseline BCVA (log MAR) was 0.78 (Snellen's equivalent 6/36) in the IVZ and 0.70 (Snellen's equivalent 6/30) in the IVB group (P = 0.78). Central macular thickness was significantly reduced at 1st, 2nd and 3rd month in the IVZ group and IVB group (P < 0.001). Conclusion: Intravitreal Ziv-Aflibercept is safe and more effective than Bevacizumab for the treatment of edema caused by diabetes mellitus, retinal vein occlusion and wet age related macular degeneration.
Publication Details
Page(s) 205-210
Published Journal: Pakistan Journal of Ophthalmology , Volume: 36, Issue: 3, Year: 2020

Request the full text from PASTIC

Keywords
Aflibercept, Ziv-Aflibercept, Wet Age related degeneration
0

Citations

0

Downloads

43

Views